Last reviewed · How we verify
COR-1
COR-1 is a monoclonal antibody targeting the PD-1 receptor.
COR-1 is a monoclonal antibody targeting the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | COR-1 |
|---|---|
| Also known as | cyclic peptide |
| Sponsor | Corimmun GmbH |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By binding to PD-1, COR-1 prevents the interaction between PD-1 and its ligands, thereby releasing the inhibition on T cells and enhancing the immune response against cancer cells.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pneumonitis
Key clinical trials
- Pilot Study of COR-1 in Heart Failure (PHASE2)
- Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody Cyclopeptide (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- COR-1 CI brief — competitive landscape report
- COR-1 updates RSS · CI watch RSS
- Corimmun GmbH portfolio CI